Clinical trial
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early…
NCT00036218 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00036218 |
|---|---|
| Title | Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease. |
| Official title | A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | sumanirole, ropinirole |
| Enrollment | 600 |
| Start date | Dec 1, 2001 |
| Completion | Apr 1, 2003 |
| First posted | May 9, 2002 |
| Last update posted | Jun 7, 2006 |
| Countries | Argentina, Mexico, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: